172 related articles for article (PubMed ID: 38833804)
21. The quest for nanoparticle-powered vaccines in cancer immunotherapy.
Sun Z; Zhao H; Ma L; Shi Y; Ji M; Sun X; Ma D; Zhou W; Huang T; Zhang D
J Nanobiotechnology; 2024 Feb; 22(1):61. PubMed ID: 38355548
[TBL] [Abstract][Full Text] [Related]
22. The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery.
Bros M; Nuhn L; Simon J; Moll L; Mailänder V; Landfester K; Grabbe S
Front Immunol; 2018; 9():1760. PubMed ID: 30116246
[TBL] [Abstract][Full Text] [Related]
23. Stimuli-Responsive Polymeric Nanovaccines Toward Next-Generation Immunotherapy.
Mao L; Ma P; Luo X; Cheng H; Wang Z; Ye E; Loh XJ; Wu YL; Li Z
ACS Nano; 2023 Jun; 17(11):9826-9849. PubMed ID: 37207347
[TBL] [Abstract][Full Text] [Related]
24. CpG-Based Nanovaccines for Cancer Immunotherapy.
Chen W; Jiang M; Yu W; Xu Z; Liu X; Jia Q; Guan X; Zhang W
Int J Nanomedicine; 2021; 16():5281-5299. PubMed ID: 34385817
[TBL] [Abstract][Full Text] [Related]
25. Multimodal stratified imaging of nanovaccines in lymph nodes for improving cancer immunotherapy.
Tian R; Ke C; Rao L; Lau J; Chen X
Adv Drug Deliv Rev; 2020; 161-162():145-160. PubMed ID: 32827558
[TBL] [Abstract][Full Text] [Related]
26. Nanovaccines: A game changing approach in the fight against infectious diseases.
Priyanka ; Abusalah MAH; Chopra H; Sharma A; Mustafa SA; Choudhary OP; Sharma M; Dhawan M; Khosla R; Loshali A; Sundriyal A; Saini J
Biomed Pharmacother; 2023 Nov; 167():115597. PubMed ID: 37783148
[TBL] [Abstract][Full Text] [Related]
27. Biomimetic Nanovaccines Potentiating Dendritic Cell Internalization via CXCR4-Mediated Macropinocytosis.
Yang C; Zhang F; Chen F; Chang Z; Zhao Y; Shao D; Sun W; Dong WF; Wang Z
Adv Healthc Mater; 2023 Feb; 12(5):e2202064. PubMed ID: 36416257
[TBL] [Abstract][Full Text] [Related]
28. Advancements in prophylactic and therapeutic nanovaccines.
Bhardwaj P; Bhatia E; Sharma S; Ahamad N; Banerjee R
Acta Biomater; 2020 May; 108():1-21. PubMed ID: 32268235
[TBL] [Abstract][Full Text] [Related]
29. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
Zhu G; Zhang F; Ni Q; Niu G; Chen X
ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
[TBL] [Abstract][Full Text] [Related]
30. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
[TBL] [Abstract][Full Text] [Related]
31. Multifunctional Biomimetic Nanovaccines Based on Photothermal and Weak-Immunostimulatory Nanoparticulate Cores for the Immunotherapy of Solid Tumors.
Li J; Huang D; Cheng R; Figueiredo P; Fontana F; Correia A; Wang S; Liu Z; Kemell M; Torrieri G; Mäkilä EM; Salonen JJ; Hirvonen J; Gao Y; Li J; Luo Z; Santos HA; Xia B
Adv Mater; 2022 Mar; 34(9):e2108012. PubMed ID: 34877724
[TBL] [Abstract][Full Text] [Related]
32. Nanoparticles for tumor immunotherapy.
Zang X; Zhao X; Hu H; Qiao M; Deng Y; Chen D
Eur J Pharm Biopharm; 2017 Jun; 115():243-256. PubMed ID: 28323111
[TBL] [Abstract][Full Text] [Related]
33. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
[TBL] [Abstract][Full Text] [Related]
34. Recent Advances of Emerging Spleen-Targeting Nanovaccines for Immunotherapy.
He X; Wang J; Tang Y; Chiang ST; Han T; Chen Q; Qian C; Shen X; Li R; Ai X
Adv Healthc Mater; 2023 Sep; 12(23):e2300351. PubMed ID: 37289567
[TBL] [Abstract][Full Text] [Related]
35. Nanovaccines in cancer immunotherapy: Focusing on dendritic cell targeting.
Achmad H; Saleh Ibrahim Y; Mohammed Al-Taee M; Gabr GA; Waheed Riaz M; Hamoud Alshahrani S; Alexis Ramírez-Coronel A; Turki Jalil A; Setia Budi H; Sawitri W; Elena Stanislavovna M; Gupta J
Int Immunopharmacol; 2022 Dec; 113(Pt B):109434. PubMed ID: 36402068
[TBL] [Abstract][Full Text] [Related]
36. Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy.
Liang K; Sun Y; Xie L; Liu Y; You Y; Xu J; Ma F; Huang Y; Song Q; Xiao W; Huang J; Gao X; Chen J
ACS Nano; 2024 Feb; 18(8):6702-6717. PubMed ID: 38359389
[TBL] [Abstract][Full Text] [Related]
37. Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach.
Kakwere H; Ingham ES; Allen R; Mahakian LM; Tam SM; Zhang H; Silvestrini MT; Lewis JS; Ferrara KW
Bioconjug Chem; 2017 Nov; 28(11):2756-2771. PubMed ID: 28956907
[TBL] [Abstract][Full Text] [Related]
38. Unlocking the power of nanomedicine: Cell membrane-derived biomimetic cancer nanovaccines for cancer treatment.
Zhao G; Wang S; Nie G; Li N
Med; 2024 Mar; ():. PubMed ID: 38582088
[TBL] [Abstract][Full Text] [Related]
39. Peptide nanovaccine in melanoma immunotherapy.
Dehghankhold M; Sadat Abolmaali S; Nezafat N; Mohammad Tamaddon A
Int Immunopharmacol; 2024 Mar; 129():111543. PubMed ID: 38301413
[TBL] [Abstract][Full Text] [Related]
40. Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses.
Yin Q; Wang Y; Xiang Y; Xu F
Hum Vaccin Immunother; 2022 Nov; 18(6):2119020. PubMed ID: 36170662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
